Bullish Case: TYRA's FGFR3 programs appear on track; TYRA's volatility surfaces reveal meaningful upside optionality priced into long-dated legs, while near-term hedging remains active. Supported by a robust cash runway and upcoming bladder cancer data in Aug (plus UTUC/achondroplasia readouts later), a positive readout could push TYRA toward the 40s+ within months, even as macro volatility keeps SPY vols elevated.

Bearish Case: Disappointing efficacy/safety signals or regulatory headwinds could reprice TYRA lower as IV compresses and hedges fade; a negative data readout may trigger a -10% to -25% move, with further downside if M&A chatter fades and near-term catalysts fail to appear.

Potential Outcomes:

1. Positive catalyst beat (25%): TYRA moves into the high-40s; long-dated calls favored.
2. Neutral data without a step-change (40%): Rangebound around 34–38.
3. Negative data shock (25%): -10% to -25% move; IV compresses.
4. Tail event (10%): strategic deal/partnership; +30%+ tail upside.

May 19, 2026